ArticleNucleic acid therapeutics2016
In Vitro Gene Silencing of the Fish Microsporidian Heterosporis saurida by RNA Interference.
Article in Nucleic acid therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Microsporidia: evolution, infection mechanisms and host impact.Nature reviews. Microbiology · 2026Review
- Charting the Future: Advanced Technologies for Sustainable Parasite Control in Aquaculture.International journal of molecular sciences · 2025Review
- A novel ATP-binding cassette protein (NoboABCG1.3) plays a role in the proliferation of Nosema bombycis.Parasitology research · 2024Article
- Transgenic overexpression of bmo-miR-6498-5p increases resistance toApplied and environmental microbiology · 2024Article
- Functional characterization of Nosema bombycis (microsporidia) trehalase 3.Parasitology research · 2023Article
- Genomic and phenotypic evolution of nematode-infecting microsporidia.PLoS pathogens · 2023Article
- Review: Recent Applications of Gene Editing in Fish Species and Aquatic Medicine.Animals : an open access journal from MDPI · 2023Review
- Silencing of heat shock protein 90 (hsp90): Effect on development and infectivity of Ichthyophthirius multifiliis.BMC veterinary research · 2023Article
- Dual RNA-seq provides novel insight into the roles ofZoological research · 2020Article
- A new age in AquaMedicine: unconventional approach in studying aquatic diseases.BMC veterinary research · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterosporis saurida, a microsporidian parasite of lizardfish, Saurida undosquamis, causes severe economic losses in marine aquaculture. Among the novel approaches being explored for treatment of parasitic infections in aquaculture is small interfering RNA molecules. The aim of the present study was to investigate the efficiency of using siRNA to knock down expression of specific genes of H. saurida in vitro. For this purpose, siRNAs specific for ATP/ADP antiporter 1 and methionine aminopeptidase II genes were designed and tested using a previously developed in vitro cultivation model. Silencing of H. saurida target genes was assessed and the efficacy of using siRNA for inhibition of gene expression was measured by quantitative real-time polymerase chain reaction (PCR). Silencing of ATP/ADP antiporter 1 or methionine aminopeptidase II by siRNA reduced H. saurida infection levels in EK-1 cells 40% and 60%, respectively, as measured by qRT-PCR and spore counts. Combined siRNA treatment of both ATP/ADP antiporter 1 and methionine aminopeptidase II siRNAs was more effective against H. saurida infection as seen by the 16S rRNA level and spore counts. Our study concluded that siRNA could be used to advance development of novel approaches to inhibit H. saurida and provide an alternative approach to combat microsporidia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.